J Korean Ophthalmol Soc.  2025 Jan;66(1):27-35. 10.3341/jkos.2025.66.1.27.

Short-term Outcomes of Ranibizumab Biosimilar CKD-701 Treatment in Macular Edema Secondary to Retinal Vein Occlusion

• Shin D
• Kim Y
• Kim JH

• KMID: 2563918
• DOI: http://doi.org/10.3341/jkos.2025.66.1.27

Abstract

Purpose
To evaluate the short-term outcomes of intravitreal injection therapy using the ranibizumab biosimilar CKD-701 in macular edema due to retinal vein occlusion.
Methods
We conducted a retrospective analysis of medical records from patients diagnosed with macular edema secondary to retinal vein occlusion who received intravitreal injections of CKD-701. The best-corrected visual acuity (BCVA) and central retinal thickness (CRT) before and after a single injection were compared. Additionally, differences in these indicators were assessed between central and branch retinal vein occlusion (CRVO/BRVO).
Results
The study included 22 subjects, with 17 cases of BRVO and 5 cases of CRVO. The efficacy was evaluated at 6.0 ± 2.2 weeks after injection. CRT decreased significantly from 534.8 ± 224.9 µm before injection to 367.8 ± 162.7 µm after injection (p < 0.001). The logarithm of the minimum angle of resolution BCVA improved significantly from 0.58 ± 0.41 to 0.48 ± 0.37 after injection (p = 0.002). The CRVO group showed a greater reduction in CRT compared to the BRVO group (p = 0.006).
Conclusions
A single injection of CKD-701 significantly improved both functional and anatomical outcomes in patients with macular edema secondary to retinal vein occlusion. Additional long-term studies are needed.

Keyword

Biosimilar, Macular edema, Retinal vein occlusion